Published online Jul 28, 2019. doi: 10.3748/wjg.v25.i28.3775
Peer-review started: March 27, 2019
First decision: May 16, 2019
Revised: June 7, 2019
Accepted: June 22, 2019
Article in press: June 23, 2019
Published online: July 28, 2019
Pancreatic cancer is known as a deadly malignancy in the world, and a sufficient treatment for the disease has not been found yet. We aimed to explore the regulatory mechanisms of microRNAs (miRNAs) in pancreatic cancer.
As a group of non-coding RNAs, miRNAs were found to paly important roles in human disease. In this study, we aimed to explore the miRNAs involved in pancreatic cancer and potential regulatory mechanisms of miR-205, which may contribute to pancreatic cancer treatment.
MiRNA expression pattern in pancreatic cancer and potential regulatory mechanisms of miR-205 and adenomatous polyposis coli (APC) were analyzed. The findings may contribute to clinical care of pancreatic cancer.
Microarray analysis was used to explore the genome-wide miRNA expression profile in pancreatic cancer. QRT-PCR and Western blot were performed to validate gene expression. Bioinformatics analysis was performed to predict target genes and their potential functions. Dual luciferase reporter assay was used to validate the binding of miR-205 and APC. Proliferation was evaluated by MTT and colony formation assays.
A large number of differentially expressed miRNAs were identified in pancreatic cancer. MiR-205 was significantly up-regulated while APC was down-regulated in pancreatic cancer. Dual luciferase reporter assay showed that APC is a validated target of miR-205. Moreover, miR-205 could promote cell proliferation in pancreatic cancer by targeting APC.
This study, for the first time, revealed that miR-205 mediated APC regulation contributed to pancreatic cancer development. Microarray analysis was used to fully disclose the genome-wide miRNAs expression profile in pancreatic cancer. Proliferation experiment showed that miR-205 could promote cell proliferation in pancreatic cancer cells by targeting APC, which could be considered as novel prognostic biomarkers for future clinical care.
The aberrantly expressed miRNAs identified in pancreatic cancer may provide valuable resources for future cancer research.